FiercePharmaOriginal article
{"a":[{"_":"Merck, Gilead’s failed Trodelvy lung cancer trial shows better China results","$":{"href":"/pharma/merck-gileads-failed-trodelvy-trial-first-line-lung-cancer-shows-better-china-results","hreflang":"en"}}]}
Phase 3negativeTrodelvyNegative
AI Analysis
Summary
Merck and Gilead's phase 3 trial of Trodelvy for first-line non-small cell lung cancer failed globally, though newly revealed data shows better results in the Chinese patient subset, raising questions about translating regional data to Western markets.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Failed first-line non-small cell lung cancer phase 3 trial; global data revealed showing better results in China subset
Importance:7/10
Sentiment:
-0.40
phase 3 failurelung canceroncologychina datatrodelvy
Read the original article
Published by FiercePharma on September 11, 2026 4:04 PM